Company Analysis
Sign in

Annexon, Inc. (ANNX)

Nasdaq: ANNX · Pharmaceutical Preparations · Brisbane, CA · filing with the SEC since 2011
Full chart Alerts Compare
Grade5.6
◀ Past 5.2● Present 5.6▶ Future 5.8
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

11 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Annexon, Inc.’s names, not what it holds today.

Patents granted
11
11 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 1 in 2024 and 2 in 2023
Applications published
33
5 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'16'17'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Annexon, Inc. its own name
named as the applicant on its applications, in US
0 granted
32 published
Annexon, Inc. its own name
US, as the owner printed on each patent
11 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,509,474Inhibitors of complement factors and uses thereofPharmaceuticalsAnnexon, Inc.
Dec 2, 202512,486,322Anti-complement factor C1q antibodies with single binding arms and uses thereofPharmaceuticalsAnnexon, Inc.
Jun 4, 202411,999,779Anti-complement factor C1q Fab fragments and uses thereofPharmaceuticalsAnnexon, Inc.
Nov 14, 202311,814,404Inhibitors of complement factors and uses thereofPharmaceuticalsAnnexon, Inc.
May 16, 202311,649,279Anti-complement factor C1Q antibodies and uses thereofPharmaceuticalsAnnexon, Inc.
Feb 23, 202110,927,167Anti-complement factor C1Q antibodies and uses thereofPharmaceuticalsAnnexon, Inc.
Jul 28, 202010,723,788Anti-complement factor C1q Fab fragments and uses thereofPharmaceuticalsAnnexon, Inc.
Mar 17, 202010,590,190Anti-complement factor C1q antibodies and uses thereofPharmaceuticalsAnnexon, Inc.
Jun 11, 201910,316,081Humanized anti-complement factor C1Q antibodiesPharmaceuticalsAnnexon, Inc.
Mar 12, 201910,227,398Anti-complement factor C1q antibodies and uses thereofPharmaceuticalsAnnexon, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 9, 20252025/0313615COMPOSITIONS AND METHODS FOR TREATING LUPUS NEPHRITISPharmaceuticalsAnnexon, Inc.
Oct 9, 20252025/0313614COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASESPharmaceuticalsAnnexon, Inc.
Jul 17, 20252025/0230225COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHYPharmaceuticalsAnnexon, Inc.
Mar 6, 20252025/0074973COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON’S DISEASEPharmaceuticalsAnnexon, Inc.
Jan 2, 20252025/0002567ANTI-COMPLEMENT FACTOR C1Q FAB FRAGMENTS AND USES THEREOFPharmaceuticalsAnnexon, Inc.
Apr 4, 20242024/0109957COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERSPharmaceuticalsAnnexon, Inc.
Apr 4, 20242024/0109920INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOFPharmaceuticalsAnnexon, Inc. · patent 12,509,474 granted from it
Mar 14, 20242024/0083989COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURYAnalysis of biological materialsAnnexon, Inc.
Mar 14, 20242024/0083987ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOFPharmaceuticalsAnnexon, Inc.
Feb 22, 20242024/0059765COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASESPharmaceuticalsAnnexon, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 11 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ANNX · research, not advice